Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease

The aim of the present study was to evaluate if the analysis of NT-proBNP might be used as an initial step for the diagnosis of chronic heart failure in patients with COPD in primary health care, and to select patients for a further examination by echocardiography.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Obstructive Pulmonary Disease Chronic Disease Chronic Heart Failure Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

65 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Primary health care center.

Olofström, Blekinge County, 29332, Sweden

About this study

Patients with a confirmed diagnosis of COPD were examined regarding chronic heart failure.

An interview regarding symptoms: breathlessness, orthopnoea, night cough, nocturia, walking distance.
Physical examination: weight and height, heart and lung auscultation, blood pressure measurement after 5 minutes' rest in the sitting position and the presence of peripheral oedema.
Electrocardiography.
Natriuretic peptide- NT-proBNP (Immulite 2500, Siemens Healthcare Diagnostics AB Sweden).
Patients with the NT-proBNP level of > 1200 pg/ml were referred for echocardiography to assess left ventricular function.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged 65 years and older with the following diagnosis codes according to International Statistical Classification of Diseases and Related Health Problems - Tenth Revision:J44 (COPD) and J41, J42 (chronic bronchitis) registered during the period 1 January 2008-16 April 2008 according to the electronic patient record.

Exclusion criteria

Impaired cognitive function and/or anticipated difficulties in carrying out spirometry due to immobility,
psychiatric disorders or terminal illness.

Treatment and study plan

Primary outcomes

Percentage of patients with elevated NT-proBNP.

Time frame: 3 months

NT-proBNP has taken only once in each patient without follow up follow up. Three months was a period when we collected data from all participants.

Secondary outcomes

Percentage of patients with abnormal left ventricular function assessed by echocardiography. Association between elevated NT-proBNP and symptoms, signs and electrocardiography.

Time frame: 3 months

Echocardiography was performed once in each referred patient. Three months was a period of data collection.

Sponsors and collaborators

Lead sponsor

Lund University

Other

Registry information

Official study title

Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease.

Acronym: NT-proBNP

Important dates

Study start: 2008
Primary completion: 2008
Study completion: 2008
First posted: Mar 1, 2013
Registry last updated: Mar 7, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed